BridgeBio Pharma Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum

Reuters

02/25

<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum

BridgeBio Pharma Inc. highlighted its rare disease pipeline and recent commercial updates in a corporate presentation. The company reported Attruby (acoramidis) net product revenue of $146 million in Q4 2025, with 7,804 unique U.S. patient prescriptions and 1,856 unique U.S. prescribing healthcare providers as of Feb. 20, 2026, and estimated more than 25% share of new-to-brand prescriptions. The presentation also outlined multiple expected 2026 milestones across programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for LGMD2I/R9, and noted it ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614728497"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614728497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614728497?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614728497","market":"nz","top_or_hot":-1,"title":"BridgeBio Pharma Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. highlighted its rare disease pipeline and recent commercial updates in a corporate presentation. The company reported Attruby (acoramidis) net product revenue of $146 million in Q4 2025, with 7,804 unique U.S. patient prescriptions and 1,856 unique U.S. prescribing healthcare providers as of Feb. 20, 2026, and estimated more than 25% share of new-to-brand prescriptions. The presentation also outlined multiple expected 2026 milestones across programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for LGMD2I/R9, and noted it ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. highlighted its rare disease pipeline and recent commercial updates in a corporate presentation. The company reported Attruby (acoramidis) net product revenue of $146 million in Q4 2025, with 7,804 unique U.S. patient prescriptions and 1,856 unique U.S. prescribing healthcare providers as of Feb. 20, 2026, and estimated more than 25% share of new-to-brand prescriptions. The presentation also outlined multiple expected 2026 milestones across programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for LGMD2I/R9, and noted it ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3BkK1Z:1","article_id":"2614728497","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614728497","pubTimestamp":1771967780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma Inc. highlighted its rare disease pipeline and recent commercial updates in a corporate presentation. The company reported Attruby  net product revenue of $146 million in Q4 2025, with 7,804 unique U.S. patient prescriptions and 1,856 unique U.S. prescribing healthcare providers as of Feb. 20, 2026, and estimated more than 25% share of new-to-brand prescriptions. The presentation also outlined multiple expected 2026 milestones across programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for LGMD2I/R9, and noted it ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"BridgeBio Pharma发布关于罕见遗传病药物管道和Attruby商业势头的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BridgeBio Pharma Publishes Corporate Presentation on Rare Genetic Disease Drug Pipeline and Attruby Commercial Momentum\n    \n\n        BridgeBio Pharma Inc. highlighted its rare disease pipeline and recent commercial updates in a corporate presentation. The company reported Attruby (acoramidis) net product revenue of $146 million in Q4 2025, with 7,804 unique U.S. patient prescriptions and 1,856 unique U.S. prescribing healthcare providers as of Feb. 20, 2026, and estimated more than 25% share of new-to-brand prescriptions. The presentation also outlined multiple expected 2026 milestones across programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia type 1, and BBP-418 for LGMD2I/R9, and noted it ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}